CELLINK announces right-sizing and sharpened commercial agenda

Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally.

BICO has entered into an agreement to divest Nanoscribe to LAB14 GmbH to an equity value of EUR 26 million.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally. 

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

In the cross-border region Medicon Valley, a new alliance is forming to highlight not just the global challenge that antimicrobial resistance (AMR) poses but the range of solutions being developed in the life science sector.